Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2022-03-24 Remuneration Information
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Grant of share options and performance shares to members of the Board of Management and key employees
Remuneration Information Classification · 95% confidence The document is a company release detailing the grant of share options and performance shares to members of the Board of Management and key employees. It discusses the remuneration policy, the valuation of these grants (Black & Scholes model), and the vesting conditions. While it touches on remuneration, it is a specific announcement of a grant program rather than a comprehensive proxy statement (DEF 14A) or a director's personal dealing report (DIRS). Given the focus on executive compensation structure and grants, it aligns best with Remuneration Information.
2022-03-24 English
Investor Presentation 2022
Investor Presentation Classification · 92% confidence The document is a press release from ALK announcing a significant regulatory development regarding their tablet treatment for house dust mite allergy in China. Specifically, they received a waiver from Chinese health authorities allowing them to file for registration in 2022 without completing the paused local Phase III study. This type of announcement, detailing strategic regulatory progress, market potential, and future filing timelines, is characteristic of an Investor Presentation (IP) or a general regulatory/corporate update. Since it is a detailed announcement about strategic progress and market outlook, rather than just a brief notice of a report being published (RPA) or a general filing (RNS), and it contains substantial strategic information often found in investor materials, 'Investor Presentation' (IP) is a strong candidate, although it reads like a formal press release. Given the options, and the focus on strategic market entry and regulatory milestones, it fits best as a high-level corporate update. However, looking closely at the definitions, it is a specific corporate announcement about regulatory progress and market strategy, which often accompanies or precedes an Investor Presentation. Since it is not a formal financial report (10-K, IR, ER) or a simple notice of publication (RPA/RNS), and it details strategic business developments, it aligns closely with the content typically found in an Investor Presentation (IP) or a Management Discussion & Analysis (MDA). Given the text focuses heavily on the strategic implications of the waiver and market size, 'IP' (Investor Presentation) is the most fitting category for this type of strategic corporate news release, although 'RNS' (Regulatory Filings) is a possible fallback. I will classify it as IP due to the strategic depth regarding market entry and regulatory strategy.
2022-03-03 Danish
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a press release from ALK announcing a significant regulatory development: receiving a waiver from Chinese authorities to file for regulatory approval for their dust mite allergy tablet without completing a paused local Phase III trial. This announcement details a specific regulatory action and its impact on future filings (2022 registration filing). It is not a full financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). Since it concerns a specific regulatory/legal development impacting the company's operations and future market access, it fits best under Legal Proceedings Report (LTR) if it were a lawsuit, but here it is a specific regulatory update concerning market access and trial requirements. Given the options, this type of announcement—a material update on regulatory hurdles being cleared for a product launch—is often classified as a general Regulatory Filing (RNS) if a more specific category like M&A (TAR) or Capital Change (CAP) doesn't apply. However, because it directly relates to the process of gaining approval and overcoming a regulatory obstacle, and it is a formal announcement of a material event, RNS is the most appropriate general regulatory fallback, as it is not a standard earnings release or management discussion.
2022-03-03 English
Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet
Regulatory Filings Classification · 95% confidence The document is a corporate press release from ALK-Abelló regarding a regulatory update in China for their allergy tablet. It provides details on a clinical study exemption and future registration plans. While it contains substantive business information, it is a standard corporate announcement released via a newswire service (GlobeNewswire) and includes a link to an attached file, fitting the criteria for a general regulatory announcement or corporate news update. Given the specific nature of the announcement (regulatory update/business development) and the lack of a more specific category like 'Earnings Release' or 'M&A', it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2022-03-03 Danish
Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet
Regulatory Filings Classification · 95% confidence The document is a press release from ALK-Abelló A/S regarding a regulatory waiver for a clinical trial in China. It provides details on the company's product development and market strategy. While it mentions an attachment, the text itself is a substantive announcement of a corporate development rather than just a notification of a report's publication. Since it does not fit into specific categories like earnings, dividends, or board changes, it falls under the general regulatory announcement category.
2022-03-03 Danish
Director's Dealing 2022
Director's Dealing Classification · 98% confidence The document title is "Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer" (Reporting of management transactions with ALK-Abelló A/S' B-shares and related securities). The text explicitly references Article 19 of the EU Market Abuse Regulation (MAR), which mandates reporting of transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to insider trading or director's dealing reports. The filing category 'Director's Dealing (Code: DIRS)' is the most appropriate fit for reporting personal share transactions by company directors and executives.
2022-03-02 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.